WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H527101
CAS#: 1331942-30-3
Description: GSK-2485852, also known as GSK-5852, is a NS5B inhibitor potentially for treatment of HCV infection.
Hodoodo Cat#: H527101
Name: GSK-2485852
CAS#: 1331942-30-3
Chemical Formula: C27H25BF2N2O6S
Exact Mass: 554.15
Molecular Weight: 554.372
Elemental Analysis: C, 58.50; H, 4.55; B, 1.95; F, 6.85; N, 5.05; O, 17.32; S, 5.78
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: GSK-2485852; GSK 2485852; GSK2485852; GSK-5852; GSK 5852; GSK5852
IUPAC/Chemical Name: (4-((N-(5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-fluorophenyl)boronic acid
InChi Key: GDSKPIAEYNJODX-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H25BF2N2O6S/c1-31-27(33)25-20-12-19(16-4-5-16)23(13-24(20)38-26(25)17-6-8-18(29)9-7-17)32(39(2,36)37)14-15-3-10-21(28(34)35)22(30)11-15/h3,6-13,16,34-35H,4-5,14H2,1-2H3,(H,31,33)
SMILES Code: OB(C1=CC=C(CN(C2=C(C3CC3)C=C4C(C(NC)=O)=C(C5=CC=C(F)C=C5)OC4=C2)S(=O)(C)=O)C=C1F)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 554.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Wilfret DA, Walker J, Voitenleitner C, Baptiste-Brown S, Lovern M, Kim J, Adkison K, Shotwell B, Mathis A, Moss L, Lee D, Yu L, Gan J, Spaltenstein A. A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects. Clin Pharmacol Drug Dev. 2014 Nov;3(6):439-48. doi: 10.1002/cpdd.142. PubMed PMID: 27129119.
2: Voitenleitner C, Crosby R, Walker J, Remlinger K, Vamathevan J, Wang A, You S, Johnson J 3rd, Woldu E, Van Horn S, Horton J, Creech K, Shotwell JB, Hong Z, Hamatake R. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5216-24. doi: 10.1128/AAC.00874-13. PubMed PMID: 23939896; PubMed Central PMCID: PMC3811320.